Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Dudley

Showing results (231-240 of 260) with videos related to

Pageof 26
Sort By:
Antimicrobial Agents and Chemotherapy|November 14, 2022
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility BreakpointsS M Bhavnani, M Trang, D C Griffith, et al.
Bioorganic & Medicinal Chemistry Letters|September 24, 2004
Quinazolinone-based fungal efflux pump inhibitors. Part 1: Discovery of an (N-methylpiperazine)-containing derivative with activity in clinically relevant Candida sppRémy C Lemoine, Tomasz W Glinka, William J Watkins, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2026
Divergent condensates tune transcriptional responses during stressJeffrey N Dudley, Joel E Berends, Chayan K De, et al.
The Journal of Infectious Diseases|January 1, 1993
2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trialM J Browne, K H Mayer, S B Chafee, et al.
Antimicrobial Agents and Chemotherapy|November 27, 2019
Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST)Jason M Pogue, Ronald N Jones, John S Bradley, et al.
The Lancet. Infectious Diseases|December 3, 2014
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensusRoger L Nation, Jian Li, Otto Cars, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 11, 2013
Consistent global approach on reporting of colistin doses to promote safe and effective useRoger L Nation, Jian Li, Otto Cars, et al.
Antimicrobial Agents and Chemotherapy|April 22, 2015
In memoriam: William A. CraigUrsula Theuretzbacher, Paul G Ambrose, Alasdair P MacGowan, et al.
Bioorganic & Medicinal Chemistry Letters|November 19, 2003
The relationship between physicochemical properties, in vitro activity and pharmacokinetic profiles of analogues of diamine-containing efflux pump inhibitorsWilliam J Watkins, Yakira Landaverry, Roger Léger, et al.
The Journal of Clinical Investigation|July 17, 2003
Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapyNelson Jumbe, Arnold Louie, Robert Leary, et al.
Pageof 26

Showing results (231-240 of 260) with videos related to

Sort By:
Pageof 26
Antimicrobial Agents and Chemotherapy|November 14, 2022
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility BreakpointsS M Bhavnani, M Trang, D C Griffith, et al.
Bioorganic & Medicinal Chemistry Letters|September 24, 2004
Quinazolinone-based fungal efflux pump inhibitors. Part 1: Discovery of an (N-methylpiperazine)-containing derivative with activity in clinically relevant Candida sppRémy C Lemoine, Tomasz W Glinka, William J Watkins, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2026
Divergent condensates tune transcriptional responses during stressJeffrey N Dudley, Joel E Berends, Chayan K De, et al.
The Journal of Infectious Diseases|January 1, 1993
2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trialM J Browne, K H Mayer, S B Chafee, et al.
Antimicrobial Agents and Chemotherapy|November 27, 2019
Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST)Jason M Pogue, Ronald N Jones, John S Bradley, et al.
The Lancet. Infectious Diseases|December 3, 2014
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensusRoger L Nation, Jian Li, Otto Cars, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 11, 2013
Consistent global approach on reporting of colistin doses to promote safe and effective useRoger L Nation, Jian Li, Otto Cars, et al.
Antimicrobial Agents and Chemotherapy|April 22, 2015
In memoriam: William A. CraigUrsula Theuretzbacher, Paul G Ambrose, Alasdair P MacGowan, et al.
Bioorganic & Medicinal Chemistry Letters|November 19, 2003
The relationship between physicochemical properties, in vitro activity and pharmacokinetic profiles of analogues of diamine-containing efflux pump inhibitorsWilliam J Watkins, Yakira Landaverry, Roger Léger, et al.
The Journal of Clinical Investigation|July 17, 2003
Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapyNelson Jumbe, Arnold Louie, Robert Leary, et al.
Pageof 26